The promise of gene therapy for inherited blood disorders like sickle cell disease and thalassemia is moving beyond experimental proof-of-concept toward clinical reality, offering hope for millions worldwide who currently rely on lifelong transfusions or face shortened lifespans. Recent advances in CRISPR-Cas9 and base editing technologies are expanding therapeutic options beyond the pioneering CTX001 treatment, which won FDA approval in 2023. Multiple gene editing strategies now show promise: directly correcting the beta-globin mutations that cause these conditions, reactivating fetal hemoglobin production to compensate for defective adult hemoglobin, and enhancing red blood cell survival. Clinical trials are demonstrating that patients can achieve transfusion independence and significant reductions in painful vaso-occlusive crises that characterize sickle cell disease. The therapeutic landscape for hemoglobinopathies represents one of gene therapy's most mature applications, with several competing approaches now in late-stage development. This convergence of multiple viable strategies could dramatically improve access and outcomes, as different editing techniques may prove optimal for specific patient populations or genetic variants. However, the complexity and cost of these personalized cell therapies remain substantial barriers to global implementation. The technology's success in blood disorders also serves as a crucial testing ground for gene editing's broader potential in treating inherited diseases, where single-gene defects create clear therapeutic targets and measurable clinical endpoints.